Exhibit 99.1 Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update LOS ALTOS, California, May 14, 2025 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended March 31, 2025, and provided a business update. "We are making incredible strides as we prepare for the potential FDA approval of oxylanthanum carbonate (OLC ...